Literature DB >> 24878791

IV Brazilian guidelines for autoantibodies on HEp-2 cells.

Paulo Luiz Carvalho Francescantonio1, Wilson de Melo Cruvinel1, Alessandra Dellavance2, Luis Eduardo Coelho Andrade2, Ben Hur Taliberti3, Carlos Alberto von Mühlen4, Carlos David Araújo Bichara5, Cleonice Bueno6, Cristóvão Luis Pitangueira Mangueira7, Darlene Gonçalves Carvalho8, Eloísa S D de O Bonfá9, Fabiano de Almeida Brito8, Flávia Ikeda e Araújo10, Jozelia Rêgo11, Kaline Medeiros Costa Pereira2, Lisiane Maria Enriconi dos Anjos12, Maria de Fatima Bissoli13, Mittermayer Barreto Santiago14, Natalya Zaidan Maluf15, Rossana Rassi Alvarenga1, Suzane Pretti Figueiredo Neves16, Valeria Valim13, Wilton Silva dos Santos17.   

Abstract

OBJECTIVE: The Fourth Brazilian Consensus for Autoantibodies Screening in HEp-2 Cells (ANA) was held in Vitória, Espírito Santo, and aimed to discuss strategies and recommendations about the technique, standardization, interpretation and quality control of the indirect immunofluorescence reaction on HEp-2 cells.
METHODS: Twenty three ANA experts from university centers and private laboratories in different areas from Brazil discussed and agreed upon recommendations for the fourth edition of the Brazilian Consensus for Autoantibodies Screening in HEp-2 Cells. RESULTS AND
CONCLUSION: The 4th ANA Consensus included three novel patterns into the existing algorithm (cytoplasmic Rods and Rings, nuclear Quasi-homogeneous, and CENP-F). Emphasis was given to the need of attention in describing the peculiar mixed pattern elicited by anti-DNA topoisomerase I (Scl-70) autoantibodies, comprising nuclear fine specked, nucleolar homogeneous pattern, NOR staining in metaphase plates, and cytoplasmic fine speckled patterns. The group also emphasized the need for continuous quality control in indirect immunofluorescence assays, the establishment of screening dilutions, as well as conjugate titration. An alert was made regarding the heterogeneity of commercial kits in defining patterns and the use of solid phase methodologies to determine the presence of autoantibodies.

Mesh:

Substances:

Year:  2014        PMID: 24878791

Source DB:  PubMed          Journal:  Rev Bras Reumatol        ISSN: 0482-5004


  11 in total

Review 1.  Advances in rheumatology practice in Brazil.

Authors:  Francisco Airton Castro Rocha; Joaquim Ivo Vasques Dantas Landim; Leila Nascimento da Rocha
Journal:  Rheumatol Int       Date:  2018-12-01       Impact factor: 2.631

2.  How to report the antinuclear antibodies (anti-cell antibodies) test on HEp-2 cells: guidelines from the ICAP initiative.

Authors:  Carlos Alberto von Mühlen; Ignacio Garcia-De La Torre; Maria Infantino; Jan Damoiseaux; Luis E C Andrade; Orlando Gabriel Carballo; Karsten Conrad; Paulo Luiz Carvalho Francescantonio; Marvin J Fritzler; Manfred Herold; Werner Klotz; Wilson de Melo Cruvinel; Tsuneyo Mimori; Minoru Satoh; Lucile Musset; Edward K L Chan
Journal:  Immunol Res       Date:  2021-10-09       Impact factor: 2.829

3.  The influence of demography and referral medical specialty on the detection of autoantibodies to HEP-2 cells in a large sample of patients.

Authors:  Wilton Ferreira Silva Santos; Ana Paula de Castro Cantuária; Daniele de Castro Félix; Leandro Kegler Nardes; Igor Cabral Santos de Melo
Journal:  Adv Rheumatol       Date:  2022-08-15

4.  VI Brazilian consensus guidelines for detection of anti-cell autoantibodies on HEp-2 cells.

Authors:  Wilson de Melo Cruvinel; Luis Eduardo Coelho Andrade; Alessandra Dellavance; Antônio Carlos Ximenes; Carlos David Araújo Bichara; Cristóvão Luis Pitangueira Mangueira; Eloísa Bonfá; Fabiano de Almeida Brito; Henrique Ataíde Mariz; Lisiane Maria Enriconi Dos Anjos; Sandra Gofinet Pasoto; Valeria Valim; Wilton Ferreira Silva Dos Santos; Clayson Moura Gomes; Roberpaulo Anacleto Neves; Paulo Luiz Carvalho Francescantonio
Journal:  Adv Rheumatol       Date:  2022-09-07

5.  Anti-nuclear antibodies in patients with breast cancer.

Authors:  R Nisihara; M C C Machoski; A Neppel; C A Maestri; I Messias-Reason; T L Skare
Journal:  Clin Exp Immunol       Date:  2018-06-14       Impact factor: 4.330

Review 6.  Standardization and Quality Assessment Under the Perspective of Automated Computer-Assisted HEp-2 Immunofluorescence Assay Systems.

Authors:  Luigi Cinquanta; Nicola Bizzaro; Giampaola Pesce
Journal:  Front Immunol       Date:  2021-02-25       Impact factor: 7.561

7.  Interkit Reproducibility of the Indirect Immunofluorescence Assay on HEp-2 Cells Depends on the Immunofluorescence Reactivity Intensity and Pattern.

Authors:  Mônica Jesus Silva; Alessandra Dellavance; Danielle Cristiane Baldo; Silvia Helena Rodrigues; Marcelle Grecco; Monica Simon Prado; Renan Agustinelli; Luís Eduardo Coelho Andrade
Journal:  Front Immunol       Date:  2022-01-19       Impact factor: 7.561

Review 8.  Report of the First International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns 2014-2015.

Authors:  Edward K L Chan; Jan Damoiseaux; Orlando Gabriel Carballo; Karsten Conrad; Wilson de Melo Cruvinel; Paulo Luiz Carvalho Francescantonio; Marvin J Fritzler; Ignacio Garcia-De La Torre; Manfred Herold; Tsuneyo Mimori; Minoru Satoh; Carlos A von Mühlen; Luis E C Andrade
Journal:  Front Immunol       Date:  2015-08-20       Impact factor: 7.561

9.  International consensus on ANA patterns (ICAP): the bumpy road towards a consensus on reporting ANA results.

Authors:  Jan Damoiseaux; Carlos A von Mühlen; Ignacio Garcia-De La Torre; Orlando Gabriel Carballo; Wilson de Melo Cruvinel; Paulo Luiz Carvalho Francescantonio; Marvin J Fritzler; Manfred Herold; Tsuneyo Mimori; Minoru Satoh; Luis E C Andrade; Edward K L Chan; Karsten Conrad
Journal:  Auto Immun Highlights       Date:  2016-01-30

10.  Relationships among Antibodies against Extractable Nuclear Antigens, Antinuclear Antibodies, and Autoimmune Diseases in a Brazilian Public Hospital.

Authors:  Fernanda Weyand Banhuk; Bruna Corrêa Pahim; Alex Sandro Jorge; Rafael Andrade Menolli
Journal:  Autoimmune Dis       Date:  2018-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.